Use of biologics in a patient with rheumatoid arthritis refractory to methotrexate

CMAJ. Canadian Medical Association Journal

Volumn 185, Issue 9, 2013, Pages 793-795

  Singh, Jasvinder A ^a,b,c  

^a BIRMINGHAM VA MEDICAL CENTER   (United States)

^b University of Alabama at Birmingham   (United States)

^c Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; ETANERCEPT; HYDROXYCHLOROQUINE; INFLUENZA VACCINE; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADL DISABILITY; ADULT; ARTHRALGIA; BONE EROSION; CASE REPORT; DISEASE DURATION; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; GENERAL PRACTITIONER; HAND RADIOGRAPHY; HUMAN; INFLUENZA; INFLUENZA VACCINATION; JOB PERFORMANCE; JOINT SWELLING; MORNING STIFFNESS; PATIENT EDUCATION; PRESCRIPTION; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SHORT SURVEY; SOCIAL LIFE; TUBERCULIN TEST; TUBERCULOSIS; WORK DISABILITY;

EID: 84878851423     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.121607     Document Type: Article

References (15)

1. Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs 2010;70:121-45.
2. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39.
3. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-103.
4. Weinblatt ME, Schiff M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 2013;65:28-38.
5. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011;(2):CD008794.
6. Singh JA, Christensen R, Wells GA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 2009;181:787-96.
7. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:4834-40.
8. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 2012;308:898-908.
9. Strangfeld A, Hierse F, Rau R, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010;12:R5.
10. Amari W, Zeringue AL, McDonald JR, et al. Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology (Oxford) 2011;50:1431-9.
11. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007;56:2886-95. (Pubitemid 47502734)
12. Dommasch E, Gelfand JM. Is there truly a risk of lymphoma from biologic therapies? Dermatol Ther 2009;22:418-30.
13. CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000;49(RR-6):1-51.
14. Kuriya B, Arkema EV, Bykerk VP, et al. Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission. Ann Rheum Dis 2010; 69: 1298-304.
15. Ma MH, Kingsley GH, Scott DL. A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2010;49:91-8.